Orthofix Medical (OFIX) to Release Quarterly Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $212.72 million for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Orthofix Medical Trading Down 0.8 %

NASDAQ OFIX traded down $0.15 during mid-day trading on Friday, hitting $17.95. The company's stock had a trading volume of 140,292 shares, compared to its average volume of 163,232. Orthofix Medical has a 52-week low of $12.08 and a 52-week high of $20.73. The stock's fifty day simple moving average is $17.94 and its two-hundred day simple moving average is $17.33. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. The firm has a market capitalization of $685.94 million, a P/E ratio of -5.73 and a beta of 1.10.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on OFIX. StockNews.com upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Friday, January 31st. Stifel Nicolaus upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating and lifted their price objective for the company from $18.00 to $24.00 in a research note on Friday, November 8th. Canaccord Genuity Group began coverage on shares of Orthofix Medical in a research note on Wednesday, January 22nd. They set a "buy" rating and a $24.00 price objective on the stock. Finally, Roth Mkm reiterated a "buy" rating and set a $22.00 price objective (up previously from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.33.

Insider Buying and Selling

In related news, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the sale, the chief financial officer now owns 28,312 shares in the company, valued at approximately $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Massimo Calafiore sold 9,203 shares of Orthofix Medical stock in a transaction on Monday, January 13th. The stock was sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the sale, the chief executive officer now owns 124,151 shares of the company's stock, valued at approximately $2,127,948.14. This trade represents a 6.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,442 shares of company stock worth $436,883. Insiders own 2.60% of the company's stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.